TY - JOUR
T1 - Recent advances in mucosal vaccines and adjuvants
AU - Allison, James P.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2002/10/1
Y1 - 2002/10/1
N2 - Mucosal vaccines may be used both to prevent mucosal infections through the activation of antimicrobial immunity and to treat systemic inflammatory diseases through the induction of antigen-specific mucosal tolerance. New, efficient mucosal adjuvants for human use have been designed based on, amongst others, bacterial toxins and their derivatives, CpG-containing DNA, and different cytokines and chemokines, with the aim of improving the induction of mucosal Th1 and Th2 responses. Mucosal delivery systems, in particular virus-like particles, have been shown to enhance the binding, uptake and half-life of the antigens, as well as target the vaccine to mucosal surfaces. DNA vaccines are currently being developed for administration at mucosal surfaces. However, there have also been failures, such as the withdrawal of an oral vaccine against rotavirus diarrhea and a nasal vaccine against influenza, because of their potential side effects.
AB - Mucosal vaccines may be used both to prevent mucosal infections through the activation of antimicrobial immunity and to treat systemic inflammatory diseases through the induction of antigen-specific mucosal tolerance. New, efficient mucosal adjuvants for human use have been designed based on, amongst others, bacterial toxins and their derivatives, CpG-containing DNA, and different cytokines and chemokines, with the aim of improving the induction of mucosal Th1 and Th2 responses. Mucosal delivery systems, in particular virus-like particles, have been shown to enhance the binding, uptake and half-life of the antigens, as well as target the vaccine to mucosal surfaces. DNA vaccines are currently being developed for administration at mucosal surfaces. However, there have also been failures, such as the withdrawal of an oral vaccine against rotavirus diarrhea and a nasal vaccine against influenza, because of their potential side effects.
UR - http://www.scopus.com/inward/record.url?scp=0036774999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036774999&partnerID=8YFLogxK
U2 - 10.1016/S0952-7915(02)00384-9
DO - 10.1016/S0952-7915(02)00384-9
M3 - Review article
C2 - 12183170
AN - SCOPUS:0036774999
SN - 0952-7915
VL - 14
SP - 666
EP - 672
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
IS - 5
ER -